Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)

Epidermolysis Bullosa Clinical Trial

Official title:

A Double-blind, Randomized, Placebo-controlled, Interventional, Multicenter, Phase III Clinical Trial to Investigate the Safety and Efficacy of ABCB5-positive Mesenchymal Stromal Cells (ABCB5+ MSCs) on Epidermolysis Bullosa (EB)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05838092
• Other study ID #: allo-APZ2-EB-III-01
• Status: Recruiting
• Phase: Phase 3
• Start date: October 18, 2023
• Est. completion date: December 1, 2025

Study information

• Verified date: October 2023
• Source: RHEACELL GmbH & Co. KG
• Contact: Cristina Daniele
• Phone: +49 6221 71833-66
• Email: cristina.daniele[@]rheacell.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this clinical trial is to investigate the safety and efficacy of allo-APZ2-OTS administered intravenously to subjects with recessive dystrophic epidermolysis bullosa (RDEB) compared to placebo.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 74
• Est. completion date: December 1, 2025
• Est. primary completion date: December 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Months and older

Eligibility

Inclusion Criteria:

1. Male or female subjects from 6 months of age with a diagnosis of RDEB confirmed by genetic testing or by a skin biopsy with immunofluorescence mapping

2. Subject is eligible to participate in this clinical trial based on general health condition;

3. Subject with a target wound meeting the following criteria: 5-50 cm2, = 21 days and < 9 months, no signs of acute infection;

4. Patient/legal representative understands the nature of the procedure and provide written informed consent/assent prior to any clinical trial procedure;

5. Women of childbearing potential must have a negative urine pregnancy test at Visit 1. Women of childbearing potential, male participants, and their partner must be willing to use highly effective contraceptive methods during the course of the entire clinical trial.

Exclusion Criteria:

1. Any current tumor diseases, including squamous cell carcinoma and basal cell carcinoma;

2. Any known allergies to components of the IP or premedication;

3. Patient/legal representative anticipated to be unwilling or unable to comply with the requirements of the protocol;

4. Pregnant or lactating women;

5. Current or previous (within 30 days of screening) treatment with another IP, or participation and/or under follow-up in another interventional clinical trial;

6. Previous participation in this clinical trial (except for screening failures);

7. Clinically significant or unstable concurrent disease or other clinical contraindications like an uncontrolled or poorly controlled mental health condition of the subject and/or his/her legal representative that could impact on patient's safety or interfere with study compliance such as inability to attend scheduled study visits; Confidential

8. Employees of the sponsor, or employees or relatives of the investigator.

Related Conditions & MeSH terms

• Epidermolysis Bullosa

Intervention

Drug:
• allo-APZ2-OTS
Allogeneic dermal ABCB5-positive Mesenchymal Stromal Cells (ABCB5+ MSCs)
• Placebo
Placebo

Locations

Country	Name	City	State
United States	Masonic Cancer Center and Medical Center Minneapolis	Minneapolis	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
RHEACELL GmbH & Co. KG

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of subjects with complete target wound closure	Proportion of subjects with complete healing of target wound, determined by the investigator, as compared to baseline	12 months
Secondary	Time to complete target wound closure from baseline		12 months